(RTTNews) - Shares of uniQure N.V. (QURE) are falling about 37 percent on Tuesday morning after the company announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the treatment of Huntington's disease. Shares of the company slipped 37.61 percent to $24.40 on the Nasdaq, compared with the previous closing price of $39.11. The stock has traded in a 52-week range of $8.73 to $71.50. At 48 months, Unified Huntington's Disease Rating Scale showed a 44% slowing of disease progression compared to the updated external control. However, the result was not statistically significant, with a p-value of 0.144. (RTTNews) - Shares of uniQure N.V.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。